Hikma Pharmaceuticals (HIK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,883.00p
   
  • Change Today:
    -8.00p
  • 52 Week High: 2,205.00p
  • 52 Week Low: 1,722.00p
  • Currency: UK Pounds
  • Shares Issued: 221.89m
  • Volume: 6,079
  • Market Cap: £4,178.10m
  • RiskGrade: 125

Wednesday broker round-up

By Conor Coyle

Date: Wednesday 02 Aug 2017

LONDON (ShareCast) - (ShareCast News) - Hikma Pharmaceuticals: Morgan Stanley downgrades to Equal Weight with a target price of 1600p.
Morrisons: HSBC upgrades to Hold with a target price of 240p.

Man Group: Citi downgrades to Neutral with a target price of 170p.

Intertek Group: Jefferies reiterates Buy with a target price of 5300p.

Rio Tinto: Macquarie reiterates Outperform with a target price of 4000p.

Reckitt Benckiser: Macquarie reiterates Outperform with a target price of 9000p.

UBM: Berenberg reiterates Sell with a target price of 675p.

AstraZeneca: Deutsche Bank reiterates Buy with a target price of 5300p.

Melrose: Goldman Sachs initiates on Buy with a target price of 270p.

SDL: Canaccord upgrades to Buy with a target price of 590p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HIK Market Data

Currency UK Pounds
Share Price 1,883.00p
Change Today -8.00p
% Change -0.42 %
52 Week High 2,205.00p
52 Week Low 1,722.00p
Volume 6,079
Shares Issued 221.89m
Market Cap £4,178.10m
RiskGrade 125

HIK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average48.07% below the market average
1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average1.96% above the sector average
Price Trend
44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average44.88% above the market average
69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average69.81% above the sector average
Income
11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average11.05% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average31.5% below the market average
39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 1
Strong Sell 0
Total 11
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

HIK Dividends

  Latest Previous
  Final Interim
Ex-Div 21-Mar-24 10-Aug-23
Paid 03-May-24 15-Sep-23
Amount 47.00¢ 25.00¢

Trades for 01-Jul-2024

Time Volume / Share Price
08:55 25 @ 1,882.00p
08:55 24 @ 1,881.00p
08:55 25 @ 1,882.00p
08:55 24 @ 1,881.00p
08:53 18 @ 1,883.00p

HIK Key Personnel

CEO Riad Mishlawi

Top of Page